08:50 AM EDT, 03/18/2025 (MT Newswires) -- Alpha Cognition ( ACOG ) said Tuesday it has commercially launched Zunveyl for the treatment of mild to moderate Alzheimer's disease.
The company said the official commercial launch provides patients with access to 5 mg, 10 mg and 15 mg doses of the treatment through a prescription.
Shares of Alpha Cognition ( ACOG ) were more than 13% higher in recent premarket activity.